119th Congress · introduced in the House · Jan 3, 2025
Reserved for the Speaker.
Official title from Congress.gov
No official summary has been published for this bill.
No cosponsors.
Includes amendment, cloture, and procedural votes. Each is labeled with its exact question; only a passage question is a vote to pass the bill.
No recorded roll calls on this bill in coverage.
LD-2 reports whose issue descriptions explicitly cite this bill (bill type and number validated against Congress.gov records). A citation does not establish the client's position or any contact with a member.
Loading lobbying reportsCoverage: reports for 2025 onward, posted Jan 1, 2025 through Oct 23, 2026.
8 citations.
AMGEN, INC. FKA HORIZON THERAPEUTICS USA, INC. · lobbying firm or registrant: S-3 GROUP
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 17, 2026 · issue area: Health Issues
$60,000
Paid to lobbying firm
H.R. 3 Lower Drug Costs Now; S. 102 Prescriptions Drug Price Relief Act of 2019
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AMGEN, INC. FKA HORIZON THERAPEUTICS USA, INC. · lobbying firm or registrant: S-3 GROUP
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 17, 2026 · issue area: Health Issues
$60,000
Paid to lobbying firm
H.R. 3 Lower Drug Costs Now; S. 102 Prescriptions Drug Price Relief Act of 2019
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AMGEN, INC. FKA HORIZON THERAPEUTICS USA, INC. · lobbying firm or registrant: S-3 GROUP
2025 Q4 report (Oct 1, 2025 – Dec 31, 2025) · posted Jan 16, 2026 · issue area: Health Issues
$60,000
Paid to lobbying firm
H.R. 3 Lower Drug Costs Now; S. 102 Prescriptions Drug Price Relief Act of 2019
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AMGEN, INC. FKA HORIZON THERAPEUTICS USA, INC. · lobbying firm or registrant: S-3 GROUP
2025 Q3 report (Jul 1, 2025 – Sep 30, 2025) · posted Oct 20, 2025 · issue area: Health Issues
$60,000
Paid to lobbying firm
H.R. 3 Lower Drug Costs Now; S. 102 Prescriptions Drug Price Relief Act of 2019
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AMGEN, INC. FKA HORIZON THERAPEUTICS USA, INC. · lobbying firm or registrant: S-3 GROUP
2025 Q2 report (Apr 1, 2025 – Jun 30, 2025) · posted Jul 18, 2025 · issue area: Health Issues
$60,000
Paid to lobbying firm
H.R. 3 Lower Drug Costs Now; S. 102 Prescriptions Drug Price Relief Act of 2019
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
THE UNIVERSITY OF CHICAGO MEDICAL CENTER · lobbying firm or registrant: CARMEN GROUP INCORPORATED
2025 Q2 report (Apr 1, 2025 – Jun 30, 2025) · posted Jul 17, 2025 · issue area: Health Issues
$68,000
Paid to lobbying firm
Medicare, Medicaid, NIH Funding; Medical Education Funding; 340B; Drug Pricing; H.R. 3; Hospital Outpatient Reimbursement; FY 2026 Appropriations; Extension of Telehealth COVID-19 rules - Telehealth; Salsa Act; Pending FDA regulation of LDTS; One…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AMGEN, INC. FKA HORIZON THERAPEUTICS USA, INC. · lobbying firm or registrant: S-3 GROUP
2025 Q1 report (Jan 1, 2025 – Mar 31, 2025) · posted Apr 21, 2025 · issue area: Health Issues
$60,000
Paid to lobbying firm
H.R. 3 Lower Drug Costs Now; S. 102 Prescriptions Drug Price Relief Act of 2019
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
THE UNIVERSITY OF CHICAGO MEDICAL CENTER · lobbying firm or registrant: CARMEN GROUP INCORPORATED
2025 Q1 report (Jan 1, 2025 – Mar 31, 2025) · posted Apr 15, 2025 · issue area: Health Issues
$68,000
Paid to lobbying firm
Medicare, Medicaid, NIH Funding; Medical Education Funding; 340B; Drug Pricing; H.R. 3; Hospital Outpatient Reimbursement; FY 2022 Omnibus Appropriations; Extension of Telehealth COVID-19 rules - Telehealth; VALID Act; Salsa Act H.R. 1835; Pendin…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing